RASSF5 and cancer: Using a powerful combination of computational protein design and directed evolution (42), we engineered RASSF5 RA domain variants that enhance its binding affinity to Ras-GTP and Ras-GDP and demonstrate that these variants inhibit Ras-associated cancer progression in lung cancer cells.